APEXCAL

K060365 · Ivoclar Vivadent, Inc. · EJK · Apr 17, 2006 · Dental

Device Facts

• Record ID: K060365
• Device Name: APEXCAL
• Applicant: Ivoclar Vivadent, Inc.
• Product Code: EJK · Dental
• Decision Date: Apr 17, 2006
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 872.3250
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

ApexCAL is a Calcium Hydroxide paste that has a creamy consistency and is suitable for several indications including: - Temporary disinfectant dressings in the obturation of root canals; - Indirect pulp capping or management of deep caries lesions; or - Direct pulp capping.

Device Story

ApexCal is a calcium hydroxide paste used in dental procedures. It is applied by a dentist or dental professional to the root canal or pulp chamber. The paste acts as a temporary disinfectant dressing for root canals or as a protective liner for direct or indirect pulp capping. It is supplied in a creamy consistency to facilitate placement. The device aids in managing deep caries and maintaining pulp vitality by providing a chemical barrier and antimicrobial environment. It is a single-use dental material.

Clinical Evidence

Bench testing only.

Technological Characteristics

Calcium hydroxide-based paste; creamy consistency; dental cavity liner; Class II device; 21 CFR 872.3250.

Indications for Use

Indicated for use as a temporary disinfectant dressing for root canal obturation, indirect pulp capping, management of deep caries lesions, and direct pulp capping in dental patients.

Regulatory Classification

Identification

A calcium hydroxide cavity liner is a device material intended to be applied to the interior of a prepared cavity before insertion of restorative material, such as amalgam, to protect the pulp of a tooth.

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the top half of the circle. Inside the circle is an emblem featuring a stylized depiction of an eagle or bird-like figure with three curved lines representing its wings or feathers.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

APR 1 7 2006

Ms. Donna Marie Hartnett Assistant Corporate Counsel Ivoclar Vivadent, Incorporated 175 Pineview Drive Amherst, New York 14228

Re: K060365

Trade/Device Name: ApexCal Regulation Number: 21 CFR 872.3250 Regulation Name: Calcium Hydroxide Cavity Liner Regulatory Class: II Product Codc: EJK Dated: April 03, 2006 Received: April 05, 2006

Dear Ms. Hartnett:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially cquivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28. 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration,

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Page 2 - Donna Marie Hartnett, Esq.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at [phone]. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely vours.

Chu S. Lin, Ph.D.

Thu S. Lin. Pl Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

## Indications for Use

510(k) Number (if known):

Device Name: ApexCal

## Indications For Use:

ApexCAL is a Calcium Hydroxide paste that has a creamy consistency and is suitable for several indications including:

KDF0365

- Temporary disinfectant dressings in the obturation of root canals; .
- Indirect pulp capping or management of deep caries lesions; or �
- Direct pulp capping. .

Prescription Use AND/OR (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)
Page 1 of __

'ny, General Hu' is not a valid word, so I am assuming it is 'ny, General Hospital'.
'KC60365' is a valid word, so I am assuming it is 'KC60365'.